IFM Investors Pty Ltd acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 4,038 shares of the life sciences company’s stock, valued at approximately $804,000.

Other hedge funds have also made changes to their positions in the company. Paradigm Asset Management Co. LLC grew its holdings in Illumina by 5.6% during the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after acquiring an additional 50 shares during the period. Patriot Financial Group Insurance Agency LLC grew its holdings in Illumina by 1.4% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock worth $528,000 after acquiring an additional 43 shares during the period. Cambridge Investment Research Advisors Inc. boosted its position in Illumina by 298.7% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 10,447 shares of the life sciences company’s stock worth $1,813,000 after purchasing an additional 7,827 shares in the last quarter. Eagle Asset Management Inc. purchased a new stake in Illumina during the second quarter worth $27,175,000. Finally, Intellectus Partners LLC boosted its position in Illumina by 6.6% during the second quarter. Intellectus Partners LLC now owns 10,783 shares of the life sciences company’s stock worth $1,871,000 after purchasing an additional 664 shares in the last quarter. 91.75% of the stock is currently owned by hedge funds and other institutional investors.

In other news, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $202.23, for a total value of $29,323.35. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $203.27, for a total value of $4,065,400.00. The disclosure for this sale can be found here. Insiders sold 136,421 shares of company stock worth $28,489,101 over the last 90 days. Company insiders own 0.89% of the company’s stock.

A number of analysts have commented on ILMN shares. Barclays boosted their target price on Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $229.00 target price on the stock in a research report on Friday, October 27th. Canaccord Genuity reiterated a “buy” rating and set a $230.00 target price (up from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Piper Jaffray Companies reiterated an “overweight” rating and set a $226.00 target price (up from $202.00) on shares of Illumina in a research report on Monday, October 9th. Finally, Janney Montgomery Scott upgraded Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $201.98.

Shares of Illumina, Inc. (NASDAQ ILMN) opened at $214.55 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. Illumina, Inc. has a 12-month low of $124.82 and a 12-month high of $230.72. The stock has a market capitalization of $31,045.44, a price-to-earnings ratio of 62.17, a PEG ratio of 3.51 and a beta of 0.79.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. During the same period in the prior year, the business earned $0.97 earnings per share. The business’s revenue was up 17.6% on a year-over-year basis. sell-side analysts anticipate that Illumina, Inc. will post 3.75 EPS for the current fiscal year.

WARNING: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/12/14/ifm-investors-pty-ltd-takes-position-in-illumina-inc-ilmn.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related stocks with our FREE daily email newsletter.